间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题,原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
高 CD3+ TILs 水平与生存改善显著相关,可作为 GC 的预后生物标志物。此外,CD3+ T 细胞浸润与 EBV 阳性和 PD-L1 阳性 GC 均相关,可能有助于免疫治疗靶点的研究。
TIL(肿瘤浸润淋巴细胞)(TILs)在肿瘤相关免疫反应中发挥调节作用,对多种癌症的预后和治疗反应具有重要意义。然而,由于其异质性,TILs在胃癌(GC)中的预后价值仍存在争议。因此,本研究旨在探讨TILs密度与GC患者预后之间的关联。
回顾性分析接受根治性胃切除术的胃腺癌患者。根据免疫组化检测的TIL强度和CD3+ T细胞浸润百分比确定分析分组。此外,还评估了Epstein-Barr病毒(EBV)、微卫星不稳定性(MSI)、CD4与CD8的T细胞比值以及程序性死亡蛋白配体1(PD-L1)状态。
共纳入345例患者:124例GC患者(35.9%)被归类为低CD3+ TIL组,221例GC患者(64.1%)被归类为高CD3+ TIL组。低分化组织学(P = .014)、EBV阳性状态(P < .001)、PD-L1阳性状态(P = .001)以及CD4 < CD8(P < .001)与高CD3+ GC相关。低CD3+组与高CD3+组之间在MSI状态、肿瘤浸润程度(pT)、淋巴结转移的存在以及pTNM分期方面无差异。在生存分析中,高CD3+组的无病生存率和总生存率优于低CD3+组(分别为P = .055和P = .041)。在多变量分析中,全胃切除术、淋巴结转移、晚期pT分期和低CD3+水平是与较差生存相关的独立因素。
Tumor-infiltrating lymphocytes (TILs) play a regulatory role in the tumor-associated immune response and are important in the prognosis and treatment response of several cancers. However, because of its heterogeneity, the prognostic value of TILs in gastric cancer (GC) is still controversial. Thus, this study aimed to investigate the association between the density of TILs and patients' outcomes in GC.
Patients with gastric adenocarcinoma who underwent curative intent gastrectomy were retrospectively investigated. The groups for analysis were determined on the basis of TIL intensity and percentage of CD3+ T-cell infiltration by immunohistochemical. Furthermore, Epstein-Barr virus (EBV), microsatellite instability (MSI), T-cell ratio of CD4 to CD8, and programmed death protein ligand 1 (PD-L1) status were evaluated.
A total of 345 patients were enrolled: 124 patients with GCs (35.9%) were classified as the low-CD3+ TIL group, and 221 patients with GCs (64.1%) were classified as the high-CD3+ TIL group. Poorly differentiated histology (P = .014), EBV-positive status (P < .001), PD-L1-positive status (P = .001), and CD4 < CD8 (P < .001) were associated with high-CD3+ GC. There was no difference regarding MSI status, the degree of tumor invasion (pT), the presence of lymph node metastasis, and pTNM stage between low- and high-CD3+ groups. In survival analysis, the high-CD3+ group had better disease-free survival and overall survival rates than had the low-CD3+ group (P = .055 and P = .041, respectively). In the multivariate analysis, total gastrectomy, lymph node metastasis, advanced pT stage, and low CD3+ levels were independent factors related to worse survival.
High CD3+ TILs levels were significantly associated with improved survival and could serve as prognostic biomarkers in GC. In addition, CD3+ T-cell infiltration was related to both EBV-positive and PD-L1-positive GC and may assist in the investigation of targets in immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。